My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Seres Therapeutics (MCRB)
NASDAQ:MCRB
MCRB nasdaq
United States
Seres Therapeutics

Seres Therapeutics Stock Analysis & Ratings

Seres Therapeutics Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Seres Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

MCRB

MCRB Stock Stats

Previous Close$6.8
Open$6.91
Bid0 x 0
Ask0 x 0
Today’s Range$6.3 - $6.91
52-Week Range$5.41 - $38.50
Volume1.26M
Average Volume1.80M
Market Cap$578.74M
Beta3.85
P/E Ratio-4.3
EPS-1.47
Earnings DateNov 11, 2021

Company Description

Seres Therapeutics

Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
Eric D. Shaff
Employees
155
ISIN
US81750R1023
Address
200 Sidney Street, Cambridge, MA, 02139, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

MCRB FAQ

What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $5.41 and its highest was $38.50 in the past 12 months.
    What is Seres Therapeutics’s market cap?
    Seres Therapeutics’s market cap is $578.74M.
      What is Seres Therapeutics’s price target?
      The average price target for Seres Therapeutics is $20.86. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $32.00 ,the lowest forecast is $7.00. The average price target represents 230.59% Increase from the current price of $6.31.
        What do analysts say about Seres Therapeutics?
        Seres Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Seres Therapeutics’s upcoming earnings report date?
          Seres Therapeutics’s upcoming earnings report date is Nov 11, 2021 which is in 24 days.
            How were Seres Therapeutics’s earnings last quarter?
            Seres Therapeutics released its earnings results on Aug 03, 2021. The company reported -$0.527 earnings per share for the quarter, missing the consensus estimate of -$0.37 by -$0.157.
              Is Seres Therapeutics overvalued?
              According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
                Does Seres Therapeutics pay dividends?
                Seres Therapeutics does not currently pay dividends.
                What is Seres Therapeutics’s EPS estimate?
                Seres Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Seres Therapeutics have?
                Seres Therapeutics has 91,720,000 shares outstanding.
                  What happened to Seres Therapeutics’s price movement after its last earnings report?
                  Seres Therapeutics reported an EPS of -$0.527 in its last earnings report, missing expectations of -$0.37. Following the earnings report the stock price went up 0.853%.
                    Which hedge fund is a major shareholder of Seres Therapeutics?
                    Among the largest hedge funds holding Seres Therapeutics’s share is ARK Investment Management LLC. It holds Seres Therapeutics’s shares valued at 232M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis